Skip to main content
. 2013 Jun 15;5(6):102–112. doi: 10.4251/wjgo.v5.i6.102

Table 2.

European Organization for Research and Treatment of Cancer metabolic response criteria for tumors evaluated with positron emission tomography

Complete metabolic response Complete resolution of [18F]-FDG uptake within the tumor volume indistinguishable from surrounding normal tissue
Partial metabolic response Reduction of a minimum of 15%-25% in tumor [18F]-FDG SUV after one cycle of chemotherapy Reduction of a minimum of > 25% in tumor [18F]-FDG SUV after more than one treatment cycle
Progressive metabolic disease Increase in [18F]-FDG tumor SUV > 25% within the tumor region, visible increase in the extent of [18F]-FDG tumor uptake (> 20% in the longest dimension) Appearance of new [18F]-FDG uptake.
Stable metabolic disease Increase in tumor [18F]-FDG SUV < 25%, decrease of < 15%. No visible increase in extent of [18F]-FDG tumor uptake (< 20% in the longest dimension)

Originated from [26], with permission. PET: Positron emission tomography; [18F]-FDG:

18

F-fluoro-de-oxyglucose; SUV: Standardized uptake value.